{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:42:51Z","timestamp":1761169371783,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jval.2020.11.016","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:58:31Z","timestamp":1613739511000},"page":"744-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA\u2019s Health Technology Assessments"],"prefix":"10.1016","volume":"24","author":[{"given":"Julia Annabel","family":"Wagle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Paul","family":"Flacke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietrich","family":"Knoerzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rg","family":"Ruof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Merkesdal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2020.11.016_bib1","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1136\/bmj.318.7192.1209","article-title":"Treatment allocation in controlled trials: why randomise?","volume":"318","author":"Altman","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2020.11.016_bib2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/RLI.0000000000000014","article-title":"Intraindividual comparison of diagnostic performance in patients with hepatic metastasis of full-dose standard and half-dose iterative reconstructions with dual-source abdominal computed tomography","volume":"49","author":"Park","year":"2014","journal-title":"Invest Radiol"},{"key":"10.1016\/j.jval.2020.11.016_bib3","unstructured":"Yim JH, Kim YK, Min JH, Lee J, Kang TW, Lee SJ. Diagnosis of recurrent HCC: intraindividual comparison of gedoxetic acid MRI and extracellular contrast-enhanced MRI."},{"issue":"Suppl 1","key":"10.1016\/j.jval.2020.11.016_bib4","doi-asserted-by":"crossref","first-page":"A258","DOI":"10.1186\/2197-425X-3-S1-A258","article-title":"Comparative analysis of diagnostic and predictive performance of novel renal biomarkes in plasma and urine of acute\u00a0kidney injury patients","volume":"3","author":"Schley","year":"2015","journal-title":"Intensive Care Med Experiment"},{"key":"10.1016\/j.jval.2020.11.016_bib5","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jcrs.2018.01.026","article-title":"Intraindividual comparison of nepafenac 0.3% for the prevention of macular edema after phacoemulsification","volume":"44","author":"Tzelikis","year":"2018","journal-title":"J\u00a0Cataract Refract Surg"},{"key":"10.1016\/j.jval.2020.11.016_bib6","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00417-016-3514-8","article-title":"Contralateral eye comparison study in MICS & MIGD: Trabectome vs iStent inject","volume":"255","author":"Gonnermann","year":"2017","journal-title":"Graefes Arch Clin Exp Opthalmol"},{"key":"10.1016\/j.jval.2020.11.016_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1159\/000319753","article-title":"Double-blind, randomized, intraindividual comparison study of the efficacy of prilocaine and\u00a0lidocaine in tumescent local anesthesia","volume":"221","author":"Augustin","year":"2010","journal-title":"Dermatology"},{"key":"10.1016\/j.jval.2020.11.016_bib8","article-title":"Evaluating the noninferiority of a new photodynamic therapy (Flexitheralight) compared with conventional treatment for actinic keratosis: protocol for a phase 2 study","volume":"26","author":"Lecompte","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"10.1016\/j.jval.2020.11.016_bib9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/jdv.15109","article-title":"Short incubation fractional CO2 laser-assisted photodynamic therapy vs. conventional photodynamic therapy in field-cancerized skin: 12-months follow-up results of a randomized intraindividual comparison study","volume":"33","author":"Vrani","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jval.2020.11.016_bib10","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/jdv.15185","article-title":"A\u00a0randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the treatment of actinic keratosis","volume":"33","author":"Dirschka","year":"2019","journal-title":"J\u00a0Eur Acad Dermatol Venerol"},{"key":"10.1016\/j.jval.2020.11.016_bib11","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1345\/aph.1A109","article-title":"Interrupted time series analysis in clinical research","volume":"37","author":"Matowe","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jval.2020.11.016_bib12","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2019001869","article-title":"A\u00a0multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors","volume":"12","author":"Young","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jval.2020.11.016_bib24","first-page":"15","article-title":"Hemophilia A and B: an overview: hospital physician","volume":"12","author":"Risal","year":"2017","journal-title":"Hematology\/Oncology"},{"key":"10.1016\/j.jval.2020.11.016_bib25","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jval.2020.11.016_bib26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1750-1172-2-40","article-title":"Hypophosphatasia","volume":"2","author":"Mornet","year":"2007","journal-title":"Orphanet J Rare Dis"},{"year":"2003","series-title":"Urea Cycle Disorders Overview. GeneReviews","author":"Mew","key":"10.1016\/j.jval.2020.11.016_bib27"},{"key":"10.1016\/j.jval.2020.11.016_bib28","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.3928\/19382359-20190327-01","article-title":"Review of cystic fibrosis","volume":"48","author":"Goetz","year":"2019","journal-title":"Pediatr Ann"},{"key":"10.1016\/j.jval.2020.11.016_bib29","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.amjmed.2005.01.059","article-title":"Evaluation and treatment of Cushing\u2019s syndrome","volume":"118","author":"Nieman","year":"2005","journal-title":"Am J Med"},{"key":"10.1016\/j.jval.2020.11.016_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jval.2020.11.016_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"NEJM"},{"key":"10.1016\/j.jval.2020.11.016_bib32","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.jval.2020.11.016_bib33","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1056\/NEJMra1615014","article-title":"Classification, ontology, and precision medicine","volume":"379","author":"Haendel","year":"2018","journal-title":"NEJM"},{"key":"10.1016\/j.jval.2020.11.016_bib37","first-page":"24","article-title":"Analysis of acceptance rate and rationales for rejection of indirect comparisons in IQWIG\u2019s benefit assessments","volume":"25","author":"Werner","year":"2020","journal-title":"Gesundh \u00f6kon Qual Manag"},{"key":"10.1016\/j.jval.2020.11.016_bib38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s40259-019-00377-y","article-title":"Evolution of the EU biosimilar framework: past and future","volume":"33","author":"Wolff-Holz","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.jval.2020.11.016_bib40","doi-asserted-by":"crossref","first-page":"k5094","DOI":"10.1136\/bmj.k5094","article-title":"Parachute use to prevent death and major trauma when jumping from aircraft: randomized controlled trial","volume":"363","author":"Yeh","year":"2018","journal-title":"BMJ"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521000395?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301521000395?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:22:36Z","timestamp":1761096156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301521000395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1098301521000395"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2020.11.016","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intraindividual Comparisons to Determine Comparative Effectiveness: Their Relevance for G-BA\u2019s Health Technology Assessments","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2020.11.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 ISPOR-The Professional Society for Health Economics and Outcomes Research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}